BrightSpring Health Services Inc. BTSG 深 沪
已收盘 11-07 16:00:00 美东时间
33.14
+0.540
+1.66%
华盛通- 最 高33.17
- 今 开32.62
- 成交量 157.12万股
- 最 低 31.965
- 昨 收 32.60
- 总市值 59.98亿
- 52周最高 35.01
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 15.26
- 委 比 -88.29%
- 总股本 1.81亿
- 历史最高 35.01
- 量 比 0.55
- 振 幅 3.70%
- 历史最低 7.85
- 每 手 1
- 风险率 4.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
BrightSpring Health Services Shines in Q3 Earnings Call
BrightSpring Health Services, Inc. (($BTSG)) has held its Q3 earnings call. Rea...
10-30 08:50
UBS Maintains Buy on BrightSpring Health, Raises Price Target to $42
UBS analyst A.J. Rice maintains BrightSpring Health (NASDAQ:BTSG) with a Buy and raises the price target from $35 to $42.
10-29 23:44
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
10-28 19:11
A Look at BrightSpring Health's Upcoming Earnings Report
BrightSpring Health (NASDAQ:BTSG) is set to give its latest quarterly earnings ...
10-28 02:02
BrightSpring announces secondary offering
BrightSpring Health Services (NASDAQ:BTSG) said certain shareholders, including an affiliate of KKR and company executives, plan to sell 15 million shares of common stock in a secondary offering. The ...
10-21 04:51
BrightSpring Health Sees Prelim Q3 Adj EPS $0.30 vs $0.27 Est; Sees Sales $3.334B vs $3.167B Est
BrightSpring Health (NASDAQ:BTSG) is looking for Prelim Q3 Adj EPS of $0.30 vs $0.27 analyst estimate. sees sales of $3.334 billion vs $3.167 billion analyst estimate.
10-21 04:30
BrightSpring Health reports preliminary third quarter revenue, increases FY25 guidance
BrightSpring Health Services, Inc. (NASDAQ:BTSG) on Monday reported preliminary third-quarter 2025 revenue of $3.33 billion, up 28% from $2.60 billion a year earlier. Adjusted EBITDA rose 37% to $160 ...
10-21 04:23
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Demystifying BrightSpring Health: Insights From 5 Analyst Reviews
During the last three months, 5 analysts shared their evaluations of BrightSpri...
10-17 22:01
